

FISCHER MEDICAL VENTURES LIMITED

(Formerly known as Fischer Chemic Limited) Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032

CIN: L86900AP1993PLC118162

Email: enquiry@fischermv.com | Website: www.fischermv.com | Contact 9080966548

March 25, 2025

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip Code: 524743

Sub: <u>Intimation from Material Subsidiary- Disclosure under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</u>

Dear Sir/Madam,

In terms of the Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform that **M/s. Time Medical International Ventures (India) Private Limited**, a Material Subsidiary of the Company, has entered into loan agreement with M/s Flynncare Health Innovations Private Limited, wholly owned subsidiary of Fischer Medical Ventures Limited.

Kindly take the above on your record.

Thanking you, Yours faithfully,

For Fischer Medical Ventures Ltd (Formerly known as Fischer Chemic Limited)

ARAVINDKUMAR V
COMPANY SECRETARY AND COMPLIANCE OFFICER

TIME MEDICAL INTERNATIONAL VENTURES (I) PVT LTD



Registered Office Address: Level 8, Prestige Palladium Bayon,

No 129-140, Greams Road, Chennai 600006 CIN: U74999TN2019PTC126835 GSTIN: 33AAHCT1130G1ZU Email: info@timemedical.in

March 25, 2025

To,

BSE Limited
Department of Corporate
Services Phiroze
Jeejeebhoy Towers, Dalal
Street, Mumbai – 400 001

Fischer Medical Ventures Ltd
(Formerly known as Fischer Chemic Ltd)

Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032

Dear Sir/ Madam,

<u>Sub: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, our Company being a Material Subsidiary to M/s. Fischer Medical Ventures Ltd (Scrip Code: 524743) hereby inform that the Board of Directors in their meeting held on 24th March 2025 have approved the Loan Agreement with FlynnCare Health Innovations Private Limited.

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are attached as Annexure to this letter.

You are requested to take the same on record.

Thanking You, Yours Truly,

For TIME MEDICAL INTERNATIONAL VENTURES(INDIA) PRIVATE LIMITED

SHANKAR VARADHARAJAN

DIRECTOR

TIME MEDICAL INTERNATIONAL VENTURES (I) PVT LTD

Registered Office Address: Level 8, Prestige Palladium Bayon,



No 129-140, Greams Road, Chennai 600006 TIME MEDICAL CIN: U74999TN2019PTC126835 GSTIN: 33AAHCT1130G1ZU Email: info@timemedical.in

Annexure A

Details of the Loan Agreement executed with by M/s Time Medical International Ventures (India) Private Limited with Flynncare Health Inoovations Private Limited as required under the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr. No.	Particulars	Details
a.	Name(s) of parties with whom the agreement is entered	Flynncare Health Innovations Private Limited. ("Borrower")
b.	Purpose of entering into the agreement	Inter Corporate Loan
C.	Size of agreement	Rs.9 Crores.
d.	Shareholding, if any, in the entity with whom the agreement is executed	Time Medical International Ventures (India) Private Limited does not hold any shares of Flynncare Health Innovations Private Limited
e.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Interest @10.50% p.a. The loan is to be given for a maximum period of 3 Years from the date of disbursement but may be extended by mutual discussion.
f.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	Yes, Flynncare Health Innovations Private Limited and Time Medical International Ventures (India) Private Limited are the wholly owned Subsidiary Company of the Fischer Medical Ventures Limited.
g.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Yes, the transaction is at arm's length basis.
h.	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not applicable

TIME MEDICAL INTERNATIONAL VENTURES (I) PVT LTD

Registered Office Address: Level 8, Prestige Palladium Bayon,

SYSTEMS

No 129-140, Greams Road, Chennai 600006 TIME MEDICAL No 129-140, Greams Road, Chennal 600000 CIN: U74999TN2019PTC126835 GSTIN: 33AAHCT1130G1ZU Email: info@timemedical.in

i.	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	Lender: M/s Time Medical International Ventures (India) Private Limited Borrower: M/s Flynncare Health Innovations Private Limited Nature of loan: Unsecured loan Amount of loan: Rs.9 Crores Date of execution of Loan Agreement: March 24, 2025 Security provided, if any: Nil Amount of loan outstanding as on date of disclosure - Nil.
j.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Nil
k.	in case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier); v. reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier)	As on date of disclosure there is no termination /amendment of the loan agreement.